A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

Overview

The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.

Full Title of Study: “A PAncreatic Cancer Screening Study in Individuals With New-Onset or DeteriOrating Diabetes MEllitus (PANDOME Study)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 19, 2028

Detailed Description

Individuals over 50 years of age who have developed new-onset diabetes mellitus (diagnosed within the past 12 months) or deteriorating diabetes will be recruited through the offices of primary care physicians and endocrinologists. Those meeting initial criteria will meet with a research APRN and will undergo a secondary screen to determine eligibility. Individuals enrolled in the study will undergo a five-minute psychological survey and donation of a blood sample for bio-bank analysis every 6 months for 3 years. MRI will be performed at baseline. Any abnormalities on MRI will be reviewed by a multi-disciplinary tumor board and discussed with the participant. Additional MRI will be performed on case-by-case basis

Interventions

  • Diagnostic Test: MRI/MRCP
    • An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed at baseline. Further imaging upon recommendation by study committee

Arms, Groups and Cohorts

  • New-Onset Diabetes Mellitus
    • Diabetes Mellitus diagnosed within the past 12 months
  • Deteriorating Diabetes Mellitus
    • History of Diabetes Mellitus with recent deteriorating within the past 6 months confirmed with repeat testing and not associated with weight gain or diabetes medication non-compliance

Clinical Trial Outcome Measures

Primary Measures

  • Early Stage Pancreatic Cancer or Precursor Lesions
    • Time Frame: Through study completion, up to 3 years
    • Determine incidence of pancreatic cancer or precursor lesions in individuals with new-onset diabetes mellitus or deteriorating diabetes

Secondary Measures

  • Relative Risk of Pancreatic Cancer Among Individuals with New-Onset Diabetes
    • Time Frame: Through study completion, up to 3 years
    • Assess utility of MRI as a screening tool for pancreatic cancer and ascertain relative risk of pancreatic cancer in study population of individuals with new-onset diabetes compared to a normal population of the same age
  • Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes
    • Time Frame: Through study completion, up to 3 years
    • Assess utility of MRI as a screening tool for pancreatic cancer and ascertain relative risk of pancreatic cancer in study population of individuals with deteriorating diabetes compared to a normal population of the same age

Participating in This Clinical Trial

Inclusion Criteria

  • Age of at least 50 years. – DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR – DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR – Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR – DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR – Deteriorating Diabetes: DM with >2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance – ECOG Performance Status of 0-1. – No known contraindications to MRI examination or gadolinium contrast. – Willing to undergo MRI and screening for metal implants or metal injury. – Recent BUN and Cr – Estimated GFR (eGFR) must be greater than 30 mL/min. – Ability to provide informed consent. – Willing to return to study site for all study assessments. Exclusion Criteria:

  • Prior history of pancreatic cancer. – Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years. – Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years). – Hereditary pancreatitis. – eGFR < 30 mL/min. – Contraindication to MRI examination or gadolinium contrast. – Pregnant or nursing women. – Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Nuvance Health
  • Provider of Information About this Clinical Study
    • Principal Investigator: Richard Frank, Director of Cancer Research – Nuvance Health
  • Overall Official(s)
    • Richard Frank, MD, Principal Investigator, Nuvance Health
  • Overall Contact(s)
    • Tammy Lo, APRN, 203-855-3551, Tammy.Lo@nuvancehealth.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.